Chronic Myeloid Leukemia (CML) is a hematological malignancy that accounts for 15% of adult leukemia cases, driven primarily by the BCR-ABL oncoprotein. Although tyrosine kinase inhibitors (TKIs) like imatinib have revolutionized CML treatment, resistance to TKIs has become a therapeutic challenge. Histone deacetylases (HDACs) play a crucial role in epigenetic modulation and are frequently upregulated in cancers, including leukemia [1-4]. In this study, we present the first demonstration of the potent anti-leukemic activity of the HDAC inhibitor martinostat in both TKI-sensitive and -resistant CML [5].
In previous studies, martinostat was identified as a specific inhibitor of HDAC class I enzymes by targeting overexpressed HDAC class I in neurological disorders [6] and prostate cancer [7]. However, we first identified martinostat as a pan-HDAC inhibitor that significantly targets HDAC classes I, II, and IV compared to the clinically approved HDAC inhibitor SAHA. Martinostat exhibited favorable drug-like properties aligned with Lipinski’s rule of five, supporting its suitability as a therapeutic candidate. Additionally, we investigated the anti-leukemic potential of martinostat in CML cell models. Martinostat selectively reduced the proliferation and viability of CML cells and induced apoptosis across multiple CML models, including imatinib-resistant cell lines and patient-derived blasts, while showing minimal cytotoxicity toward healthy cells and low developmental toxicity in zebrafish embryos.
Martinostat induced apoptosis by activating caspase pathways and promoting immunogenic cell death through HMGB1 release. Transmission electron microscopy (TEM) observations indicated morphological changes and increased autophagic activity following martinostat treatment. In mRNA-seq analysis, martinostat treatment significantly impacted key gene pathways related to leukemia cell survival and proliferation. These findings collectively support martinostat’s potential as a therapeutic agent for CML.
Regarding the HDAC inhibitory effect, martinostat induced histone acetylation at significantly lower concentrations than SAHA, indicating enhanced potency in epigenetic modulation. Compared to SAHA, martinostat more efficiently suppressed leukemic colony formation, elicited morphological alterations, and modified cell distribution and proliferative capacity. Computational docking studies revealed that martinostat interacts with the binding pocket of HDAC isoenzymes in a similar manner to SAHA; however, in detailed docking simulations, martinostat exhibited notably stronger binding affinity for selected HDAC isoenzymes than SAHA, reinforcing its potential as a more effective HDAC inhibitor.
In combination with TKI imatinib, martinostat exhibited a synergistic effect in both imatinib-sensitive and resistant CML cells. Against the BCR-ABL molecular pathway, the primary cause of CML, the combination of martinostat and imatinib abolished the activation of the BCR-ABL and STAT5 pathways by overcoming TKI resistance and inducing cell death compared to treatment with either martinostat or imatinib alone. This synergy was validated in vivo using a mouse xenograft model, as evidenced by significantly inhibited tumor growth and reduced tumor volume while causing no organ damage in the mice.
Collectively, these findings underscore martinostat's potential as a selective, low-toxicity HDACi with notable anti-cancer effects in CML. To address TKI resistance, martinostat emerges as a promising therapeutic candidate in combination with imatinib, potentially offering an effective strategy for enhancing CML treatment outcomes.
A mechanistic overview describing the effect of Martinostat.
Created in BioRender. Yang, H and Diederich, M. (2025)
References:
1. Losson H, Schnekenburger M, Dicato M, Diederich M: HDAC6-an Emerging Target Against Chronic Myeloid Leukemia? Cancers (Basel) 2020, 12(2).
2. Losson H, Gajulapalli SR, Lernoux M, Lee JY, Mazumder A, Gerard D, Seidel C, Hahn H, Christov C, Dicato M et al: The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. Pharmacol Res 2020, 160:105058.
3. Lernoux M, Schnekenburger M, Losson H, Vermeulen K, Hahn H, Gerard D, Lee JY, Mazumder A, Ahamed M, Christov C et al: Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells. Clin Epigenetics 2020, 12(1):69.
4. Lernoux M, Schnekenburger M, Dicato M, Diederich M: Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia. Biochem Pharmacol 2020, 173:113698.
5. Yang H, Li V, Park SJ, Cheon SW, Lorant A, Mazumder A, Lee JY, Orlikova-Boyer B, Cerella C, Christov C et al: Martinostat as a novel HDAC inhibitor to overcome tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Clinical Epigenetics 2025, 17(1):125.
6. Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, Kang MS, Mathotaarachchi S, Benedet AL, Therriault J et al: [(11)C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer's disease. Nat Commun 2022, 13(1):4171.
7. Chen Z, Wang X, Yang X, Xu Y, Yang Y, Wang H, Li T, Bai P, Yuan G, Chen H et al: Imaging assisted evaluation of antitumor efficacy of a new histone deacetylase inhibitor in the castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 2021, 48(1):53-66.